On the 17th January the company called AMP945 “best-in-class” You don’t throw that word around unless you can back it up with data.
We don’t have to wait to long to hear about efficacy readouts either “trial will initially enrol 26 patients over the coming months and an interim analysis of efficacy will then be conducted in mid-24”
The company will need to raise capital in the short to medium term hence the reluctance of retail to push the needle now. There is no rush especially as any cap raise will be done at a discount to the share price.
If efficacy readouts are compelling, retail will buy in. Any partner is probably waiting to see that data too. Partnership in H2 2024 seems realistic subject to compelling efficacy data. Once again retail is probably waiting for that external validation from a pharma partner too.
ATX Price at posting:
8.2¢ Sentiment: None Disclosure: Held
